| To observe clinical curative effect and drug safety of the Bupleurum Liver-Coursing Powder combined adefovir dipivoxil (ADV), lamivudine (LAM) in the treatment of hepatitis B correlation compensatory stage liver cirrhosis. Methods: Sixty cases of patients with hepatitis B correlation compensatory stage liver cirrhosis who received and cured in our hospital during April 2011 to April 2013 were included in the study, according to admission order, 60 patients were divided into ADV + LAM group, as well as the combination of traditional Chinese and western medicine group, 30 cases in each group, including lamivudine combined adefovir were used in the ADV + LAM group, combination of Chinese and western group applied Bupleurum Liver-Coursing Powder on the basic scheme of ADV + LAM group, both of the two groups were treated for 48 weeks. Observe the complications of patients after 48 weeks of treatment and the occurrence of hepatocellular carcinoma (HCC). At the same time, record the changes of the concentration of HBV DNA, liver function parameter and ultrasound examination results. Results: 1) After 48 weeks of treatment and follow-up, 10 patients showed complications or hepatocellular carcinoma, accounted for 16.67%, 7 cases in the ADV + LAM group (3 cases of ascites, 1 case of hepatocellular carcinoma, 2 cases of esophageal varices, 1 case of hepatic encephalopathy), 1 case of combination of traditional Chinese and western medicine group (1 case of esophageal varices). The incidence of complications and hepatocellular carcinoma (HCC) between the two groups were with significant differences, P=0.02, C2=3.68. Using logistic regression analysis, it was concluded that age or gender was not the independent risk factors in complications of cirrhosis or hepatocellular carcinoma (HCC) (P> 0.05), and HBeAg condition, HBV-DNA loads were both the independent risk factors for complications of cirrhosis or hepatocellular carcinoma (P< 0.05). 2) HBV DNA overcast rate of ADV + LAM group at 12 weeks, 24 weeks, 36weeks, 48 weeks after the treatment were respectively 50.5%, 57.3%, 64.9%, 87.6%, HBV DNA overcast rate of combine traditional Chinese and western medicine group were respectively 50.8%, 59.7%, 85.7%, 96.4%, HBV DNA overcast rates of the two groups at 12 weeks and 24 weeks after the treatment were with no statistical differences (P=0.34 t1=4.24; P2=0.25 t2=4.92). HBV DNA overcast rates of the two groups at 36 weeks and 48 weeks after treatment, were with statistically significant (P3=0.03 t1=5.91; P4=0.03 t2=5.92). 3)Forty-eight weeks after treatment, serum alanine aminotransferase (ALT), aspartate transamin ase (AST), blood urea nitrogen (BUN), creatinine (Cr), serum albumin (ALB), total bilirubin (TBIL) of the combine traditional Chinese and western medicine group had improved the most obvious. Compared incidence of adverse reactions in the 2 groups, were with significant differences P=0.032, C2=3.82, symptoms disappeared after symptomatic treatment in all the patients, with no patients with renal insufficiency. Conclusion: By suppressing HBV replication, Bupleurum Liver-Coursing Powder can partly reverse the development of reverse cirrhosis, thus is recommended in the clinical application. |
